Navigation Links
FDA Approves Zolgensma, Landmark AAV-Delivered Gene Therapy to Treat Spinal Muscular Atrophy
Date:5/26/2019

Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular atrophy (SMA) also known as AVXS-101, was approved for clinical use in the United States by the Food and Drug Administration today.

The treatment is now both the second virally-delivered gene therapy approved to treat inherited genetic disorders in the United States and the second-ever approved treatment for SMA.

FDA granted priority review status to developer AveXis in December 2018, The therapy previously received Breakthrough Therapy designation in the US and remains in the European Medical Agency’s PRIority MEdicines (PRIME) program, both designed to facilitate efficient development of medicines.

“More than another clinical landmark for translational science in gene therapy, the approval of Zolgensma provides hope for thousands of families affected by SMA in the United States,” Guangping Gao, Ph.D., President of the American Society of Gene and Cell Therapy and director of the Horae Gene Therapy Center at the University of Massachusetts Medical School says. “The road from the lab to the clinic is always long and arduous, but we expect to see accelerating approvals in gene and cell therapy as the basic and translational science proves safe and effective. Congratulations to all involved in the development of Zolgensma and thank you to the patients and families who have participated in all levels of tests and trials.”

In clinical trial updates presented at the American Society of Gene & Cell Therapy’s 22nd Annual Meeting on April 29, all 12 infants treated with Zolgensma had event-free survival and 92 percent demonstrated Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) scores over 40 six months following treatment compared with just 38.5% of patients treated with the sole alternative treatment for SMA. Totals for the CHOP-INTEND test range from 0 to 64 with higher scores indicating better motor skills.

In clinical trial data supporting Zolgensma’s priority review application, all 15 patients infused with Zolgensma were alive and without the need for permanent ventilation at 24 months, and 11 of 12 patients could sit unassisted for at least 5 seconds. Patients monitored as part of an ongoing observational long-term follow-up maintained their developmental motor milestones and some achieved additional motor milestones.

About SMA
Spinal Muscular Atrophy (SMA) is a rare genetic disease that affects the motor nerve cells in the spinal cord and is the leading genetic cause of infant mortality. It is caused by an inherited faulty SMN1 gene. The SMN1 gene helps provide instructions to cells on how to produce the SMN (survival motor neuron) protein. If there isn’t enough correct SMN protein produced, it leads to degeneration, meaning decline or deterioration, of motor neurons. This creates problems with a person’s physical strength, often taking away the ability to walk, eat or even breathe. ASGCT has created educational resources for families of patients affected by SMA at asgct.org/education/spinal-muscular-atrophy.

About ASGCT
The American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Read the full story at https://www.prweb.com/releases/fda_approves_zolgensma_landmark_aav_delivered_gene_therapy_to_treat_spinal_muscular_atrophy/prweb16337373.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. NSF approves planning grant for Center for Advanced Research in Drying
2. FDA approves lipodystrophy drug metreleptin
3. German Research Foundation approves new priority program in the life sciences
4. FDA approves game changing drug for melanoma
5. Lifesaving HIV treatment could reach millions more people following landmark study
6. Landmark report sets priorities to address malnutrition
7. Findings announced from landmark study on safety of adolescent bariatric surgery
8. Landmark egg production study reveals reduction in environmental impact over past 50 years
9. University of Strathclyde and NYU join in landmark research and academic partnership
10. Grants will fund landmark aging research at Waterloo
11. Law Firm Carey Rodriguez Obtains First-Of-Its-Kind Ruling In Landmark Biometric Privacy Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... Fla. (PRWEB) , ... August 14, 2019 , ... ... to broadcast 4Q/2019, will explore how developments in microbiome therapeutics are helping to ... local listings for more information. , Advancements will educate about the DECODE.DESIGN.CURE™ technology ...
(Date:8/14/2019)... ... August 14, 2019 , ... Join Jonathan Riek, PhD, VP, ... on Tuesday, September 10, 2019 at 1pm EDT to learn about two common imaging ... , NAFLD is the most common diffuse liver disease, with a worldwide prevalence ...
(Date:8/14/2019)... JOLLA, Calif. (PRWEB) , ... August 14, 2019 , ... ... insight into their future children, announces inclusion in the 38th annual Inc. 500|5000 ... been eligible to apply. To qualify, companies must have been founded and generating revenue ...
Breaking Biology News(10 mins):
(Date:8/7/2019)... ... ... Locus Agricultural Solutions (Locus AG) reports record levels of carbon sequestered in ... ® , which is pulling up to 121% more carbon into the soil than ... from the treatment of almonds, cherries, turf/sod, grapes and citrus across the U.S., as ...
(Date:8/6/2019)... ... August 06, 2019 , ... Shoreline Biome, ... the strain level, has announced partnerships with six international distributors. , The ... research organizations in Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New Zealand, Singapore, the ...
(Date:8/6/2019)... EDWARDSVILLE, Ill. (PRWEB) , ... August 06, 2019 ... ... to Southern Illinois University Edwardsville for the launch of a community project that ... , The three-year grant supports the project, entitled “A Youth-Led Citizen Science Network ...
(Date:7/30/2019)... ... July 30, 2019 , ... ... team building and cooking events company. Not only has the company already hosted ... started offering Private Cooking Parties to its guests. , With Lajollacooks4u’s Private Cooking ...
Breaking Biology Technology: